20 medical and research teams working together
 to improve vision and overcome disabilities


Pitié-Salpêtrière Hospital location :

-Effet of adalimumab for the treatment of uveitis in juvenile idiopathic arthritis (ADJUVITE) Purpose : the investigators propose to study the efficacy of adalimumab versus placebo (double blind randomization) on reduction of ocular inflammation quantified by laser flare photometry after 2 months of treatment in patients with active uveitis despite well conducted treatment with steroid eye drops and MTX. After the second month, all patients wishing to continue the trial and presenting a satisfactory cinical state will be treated with adalimumab for a total of one year after inclusion to descriptively evaluate the efficacy and safety of treatment over 10 to 12 months.

-Regulatory T Cell Therapy in Ocular Inflammation (Uvereg). Administration of CD4+CD25+FOXP3+ natural regulatory T-cells (Tregs) inautoimmune diseases is a promising therapeutic strategy. Since low numbers of polyclonal Tregs regulate uveitis in experimental uveitis mouse model, a prospective phase I/II clinical trial of Treg cellular therapy is ungoing in patients with severe uveitis who are refractory to conventional treatments.


CHNO des Quinze-Vingts- CIC 1423 location:

-Monitoring retinal vasculitis by adaptive optics imaging. Adaptive optics is a technique used in retinal imaging systems to reduce optical aberrations. We recently reported that adaptive optics (AO) en face imaging has a great sensitivity to detect retinal vasculitis, in some cases superior to fluorescein angiography. We investigate the potential interest of AO imaging for monitoring retinal vasculitis.

-Imaging retinal vessels in patients with Multiple sclerosis, neuromyelitis optica, and optic neuritis. Patients from the Department of Neurology (Pitié-Salpêtrière and CHNO des Quinze-Vingts) referred to our division receive a complete evaluation, including: testing of visual acuity, fundus examination, color fundus photographs, fluorescein angiography if vasculitis detected, AO infrared flood-imaging (rtx1 camera, ImagineEye, Orsay, France). The aim of the study is to detect any visible signs of retinal vasculitis and comparing them to the evolution of the systemic disease. Studies supported by the Institut National de la Santé et de la Recherche Médicale and the Agence Nationale de la Recherche (ANR-09-TECS-009 and ANR-12-TECS-0015-03).


Multicenter clinical trials:

Those programs aim to assess the clincal efficay and safety of new biologics as investigative medication for non infectious intermediate and posterior uveitis :

- EYEGUARD study: evaluate gevokizumab, on patients with active (EYEGUARD-A™) or controlled (EYEGUARD-C™) non-infectious intermediate, posterior, or pan-uveitis. (laboratoire XOMA). CHNO des Quinze-Vingts and Pitié-Salpêtrière hospital locations
- SATURNE study a multicentered study investigating the efficacy and safety of sarilumab in patients with non infectious uveitis (laboratoire Sanofi). CHNO des Quinze-Vingts and Pitié-Salpêtrière locations
- VISUAL, efficacity and safety of adalimumabin subjects with active uveitis (Visual I) and inactive uveitis (Visual II) (laboratoire Abbvie). CHNO des Quinze-Vingts locations.
- The SAKURA Study, a Phase III, Multicenter, Randomized, Double-Masked, Study of Intravitreal Injections of DE-109 for the Treatment of Active, Noninfectious Uveitis of the Posterior Segment. Pitié-Salpêtrière hospital location.